Duality Advisers’s BridgeBio Pharma BBIO Stock Holding History

Duality Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-73,679	Closed	-$2.28M	–	60
2024 Q1	$2.28M	Sell	73,679 -6,513	-8%	-$221K	0.22%	159
2023 Q4	$3.24M	Buy	80,192 +31,036	+63%	+$932K	0.34%	87
2023 Q3	$1.3M	Buy	+49,156	New	+$1.39M	0.16%	237
2023 Q2	–	Sell	-41,972	Closed	-$696K	–	521
2023 Q1	$696K	Buy	+41,972	New	+$489K	0.08%	360
2022 Q1	–	Sell	-216,254	Closed	-$3.61M	–	637
2021 Q4	$3.61M	Buy	216,254 +180,298	+501%	+$7.63M	0.39%	73
2021 Q3	$1.69M	Buy	35,956 +10,174	+39%	+$545K	0.13%	272
2021 Q2	$1.57M	Buy	+25,782	New	+$1.47M	0.14%	252

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Duality Advisers's BBIO Position: Q2 2024 in Review

Duality Advisers sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 73,679 shares — an estimated $2.28M sold.

Duality Advisers first reported a position in BBIO in Q2 2021 and held it in 7 quarters. The position peaked at $3.61M in Q4 2021. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

Duality Advisers reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
Duality Advisers sold 73,679 BridgeBio Pharma shares in Q2 2024, an estimated $2.28M.
Duality Advisers first reported a position in BridgeBio Pharma in Q2 2021 and held it in 7 quarters.
Duality Advisers's BridgeBio Pharma position peaked at $3.61M in Q4 2021.
251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.